Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Relay Therapeutics ( (RLAY) ) has shared an update.
On June 6, 2025, Relay Therapeutics held its 2025 Annual Meeting of Stockholders, where three key proposals were voted on. The stockholders elected Alexis Borisy and Mark Murcko, Ph.D., as class II directors for a three-year term, approved executive compensation on a non-binding advisory basis, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its future direction and stakeholder confidence.
The most recent analyst rating on (RLAY) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Relay Therapeutics stock, see the RLAY Stock Forecast page.
Spark’s Take on RLAY Stock
According to Spark, TipRanks’ AI Analyst, RLAY is a Neutral.
The overall stock score is primarily impacted by financial performance challenges, notably negative profitability and cash flow concerns. Technical analysis indicates short-term bullish momentum, but long-term trends remain weak. The strategic lease termination provides a positive offset through cost savings, although the valuation remains unattractive due to negative earnings.
To see Spark’s full report on RLAY stock, click here.
More about Relay Therapeutics
Relay Therapeutics, Inc. operates in the biotechnology industry, focusing on developing precision medicines for cancer and genetic diseases. The company leverages its proprietary Dynamo platform to design and develop novel therapeutics.
Average Trading Volume: 2,458,437
Technical Sentiment Signal: Sell
Current Market Cap: $553.8M
See more insights into RLAY stock on TipRanks’ Stock Analysis page.